Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection.

Next Previous
X
Search
Trial Profile

A Randomised, Double-blind, Placebo-controlled, Phase IIa Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Lytixar (LTX-109) in Patients With Uncomplicated, Gram-positive, Skin Infection.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LTX 109 (Primary)
  • Indications Gram-positive infections; Skin infections
  • Focus Adverse reactions
  • Sponsors Lytix Biopharma

    • Most Recent Events

    • 27 Apr 2012 Planned number of patients changed from 24 to 35 as reported by European Clinical Trials Database record.
    • 15 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Actual initiation date (September 2010), official title, lead investigators identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top